Recent clinical trial data suggested that increased Th1/Th17 cells (CD4+ T cell subpopulation) in CNS tissue, cerebrospinal fluid, and blood predominate in the pathogenesis of MS (8), so we focused on target genes and target pathways that target CD4+ T cells. This evidence concerns the gene CD4 and myeloid sarcoma.